Advertisement

TheBodyPRO.com Covers IAS 2015

News

HIV Remission for More Than 12 Years After Very Early Treatment in French Teenager

July 21, 2015

An 18-year-old female has been able to maintain an undetectable viral load for more than 12 years after interrupting early antiretroviral therapy, according to a study presented at IAS 2015, in Vancouver, Canada.

Speaking on behalf of the study researchers, Asier Saez-Cirion, Ph.D., presented data detailing the teenager's continued HIV remission, which the researchers define as:

HIV remission should allow patients to durably discontinue therapeutic intervention, without (i) developing HIV-associated morbidities, (ii) showing decline of clinical parameters or progression to disease, (iii) while maintaining viremia at the lowest levels to avoid enhancing risk of transmission of infection.

For background, since 1996, the ANRS pediatric cohort known as CO10 EPF has followed 187 children born with HIV, 100 of whom have received combination antiretroviral therapy before 6 months of age. Of those, 15 have interrupted treatment while their viral loads were below 500 (the average time on treatment was 33 months).

Advertisement

The researchers estimated the probability was 13% for these 15 children to still control HIV two years after treatment interruption. Of the 15 children, 13 lost control of the virus within a year, while one was able to control the virus for over three years before viral rebound. The young woman, however, has continued to control the virus for over 12 years.

The teenager was infected during birth and was given zidovudine (AZT, Retrovir) as prophylactic treatment. She had an undetectable HIV-RNA viral load at day 3, and an undetectable HIV-DNA viral load at days 3 and 14. After six weeks, the zidovudine treatment was interrupted. At three months, her viral load increased sharply and she was started on combination antiretroviral therapy.

The girl was then lost to follow-up between 5.8 and 6.8 years of age, but when she returned to care she had an undetectable viral load despite interrupting treatment months earlier.

Since then, despite not being on treatment, the young woman's viral load has been below 50 (except for one blip of 515) for over 12 years. HIV DNA has consistently been detected in her circulating CD4+ cells at very low levels, however viremia is undetectable (although viral replication can be induced in vitro). Additionally, her CD4+ cell count has remained stable.

Interestingly, like the adults in the ANRS VISCONTI study (who have been able to control HIV without treatment after very early initiation of antiretroviral therapy), the teenager does not have a favorable HLA background for controlling HIV infection.

Nevertheless, this is the first case that shows that very long-term HIV remission is possible after very early treatment in perinatally infected children.

"Understanding the ability to durably contain HIV replication may guide new strategies towards HIV remission," the researchers concluded.

Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.

Follow Warren on Twitter: @WarrenAtTheBody.


Copyright © 2015 Remedy Health Media, LLC. All rights reserved.




This article was provided by TheBodyPRO.com. It is a part of the publication The 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.
 


 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.